제론 (GERN) 주가

제론(GERN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.30 (-1.52%), 시가총액 $0.81B, 52주 최저~최고 $1.07 ~ $1.95.

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatm

핵심 지표

• 현재가: $1.30 (-1.52%)
• 시가총액: $0.81B
• 52주 최저~최고: $1.07 ~ $1.95
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

제론의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

제론 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.1111

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 3.51
• 순이익률: -0.34%
• 영업이익률: -0.00%

자주 묻는 질문